Huangqi injection (a traditional Chinese patent medicine) for chronic heart failure: a systematic review.
Huangqi injection (a traditional Chinese patent medicine) for chronic heart failure: a systematic review.
复制标题
DOI：
10.1371/journal.pone.0019604
复制
发表时间：
2011-05-06
期刊：
影响因子：
3.7
通讯作者：
Raschetti R
中科院分区：
文献类型：
--
作者：
Fu S;Zhang J;Menniti-Ippolito F;Gao X;Galeotti F;Massari M;Hu L;Zhang B;Ferrelli R;Fauci A;Firenzuoli F;Shang H;Guerra R;Raschetti R
慢性心力衰竭（CHF）是一个全球性的公共卫生问题。因此，需要副作用少的新型有效药物。早期文献研究表明，黄芪注射液是我国治疗CHF最常用的中成药之一。随着大量临床研究的开展和发表，评价黄芪注射液的有效性和安全性至关重要。因此，我们在中意联合实验室（JoSIL）的支持下进行了这项系统评价。根据现有科学知识评价黄芪注射液治疗CHF的有效性和安全性。对PubMed、EMBASE、CBM、科克伦图书馆和中文文献数据库进行了广泛检索，检索时间截止到2008年7月。检索关于黄芪注射液治疗CHF的临床试验，不考虑语言。根据科克伦评价者手册5.0对各试验进行质量评价，采用科克伦协作网提供的RevMan 5.0和STATA 9.2进行数据分析。在选择了1，205篇文献后，纳入了62篇在中国进行并在中国期刊上发表的RCT和准RCT。试验的方法学质量较低。在大多数试验中，未指定入选和排除标准。此外，只有一项研究在足够长的时间后评价了药物疗效的结局。由于这些原因以及不同的基线特征，我们没有进行荟萃分析。虽然现有的研究还不足以对黄芪注射液（一种中成药）的有效性和安全性得出结论，但我们希望我们的工作能为黄芪注射液的进一步研究提供有益的经验。中医药临床研究的整体水平有待提高，使中医药的疗效得到国际社会的评价，并有可能使部分中药进入国际市场。
Chronic heart failure (CHF) is a global public health problem. Therefore, novel and effective drugs that show few side-effects are needed. Early literature studies indicated that Huangqi injection is one of the most commonly used traditional Chinese patent medicines for CHF in China. As a large number of clinical studies has been carried out and published, it is essential to evaluate the effectiveness and safety of Huangqi injection. Therefore, we carried out this systematic review under the support of the framework of the Joint Sino-Italian Laboratory (JoSIL). To evaluate the efficacy and safety of Huangqi injection for CHF according to the available scientific knowledge. An extensive search including PubMed, EMBASE, CBM, the Cochrane Library and Chinese literature databases was performed up to July 2008. Clinical trials regarding Huangqi injection for the treatment of CHF were searched for, irrespective of languages. The quality of each trial was assessed according to the Cochrane Reviewers' Handbook 5.0, and RevMan 5.0 provided by the Cochrane Collaboration and STATA 9.2 were used for data analysis. After selection of 1,205 articles, 62 RCTs and quasi-RCTs conducted in China and published in Chinese journals were included in the review. The methodological quality of the trials was low. In most trials inclusion and exclusion criteria were not specified. Furthermore, only one study evaluated the outcomes for drug efficacy after an adequate period of time. For these reasons and because of the different baseline characteristics we did not conduct a meta-analysis. Although available studies are not adequate to draw a conclusion on the efficacy and safety of Huangqi injection (a traditional Chinese patent medicine), we hope that our work could provide useful experience on further studies on Huangqi injections. The overall level of TCM clinical research needs to be improved so that the efficacy of TCM can be evaluated by the international community and possibly some TCM can enter into the international market.
影响因子：
3.7
作者：
Denzler KL;Waters R;Jacobs BL;Rochon Y;Langland JO
通讯作者：
Langland JO
影响因子：
9.7
作者：
Cho, William C. S.;Leung, Kwok N.
通讯作者：
Leung, Kwok N.
影响因子：
1.6
作者：
Ernst, E.;Lee, M. S.
通讯作者：
Lee, M. S.